Last reviewed 2026-04-22 · How we verify

Hemoblast Bellows application

Hemoblast Bellows is a hemostatic agent that combines a thrombin-based collagen sponge with a bellows applicator to achieve rapid hemostasis at surgical bleeding sites.

Hemoblast Bellows is a hemostatic agent that combines a thrombin-based collagen sponge with a bellows applicator to achieve rapid hemostasis at surgical bleeding sites. Used for Hemostasis during surgical procedures where bleeding control is needed.

At a glance

Mechanism of action

The product consists of a collagen-based matrix impregnated with thrombin that promotes clot formation when applied directly to bleeding tissue. The bellows applicator delivers the hemostatic agent with controlled pressure to ensure optimal contact and absorption at the wound site, facilitating rapid platelet aggregation and fibrin deposition.

Approved indications

• Hemostasis during surgical procedures where bleeding control is needed

Common side effects

• Infection at application site
• Hematoma formation
• Allergic reaction

Key clinical trials

• sTErnAl heMostasiS Trial (PHASE4)
• Clinical Study Evaluating the Performance of HEMOBLAST Bellows Compared to FLOSEAL Hemostatic Matrix in Cardiothoracic Operations (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Hemoblast Bellows application CI brief — competitive landscape report
• Hemoblast Bellows application updates RSS · CI watch RSS
• WakeMed Health and Hospitals portfolio CI